Cytosorbents Corporation (CTSO)
Chart Events
Performance Outlook
| Previous Close | 8.35 |
| Open | 8.41 |
| Bid | 8.63 x 1100 |
| Ask | 8.81 x 1000 |
| Day's Range | 8.35 - 8.86 |
| 52 Week Range | 6.99 - 11.68 |
| Volume | 469,335 |
| Avg. Volume | 292,001 |
| Market Cap | 378.611M |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.24 |
| Earnings Date | Nov 02, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.60 |
Fair Value
Related Research
- Cytosorbents CorporationCOLL: Lowering target price to $16.00COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of SELL; a target price of $16.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat4 days agoArgus Research
- PR Newswire
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar to provide a global perspective on CytoSorb® blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT / 5:00 p.m. CET. The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COV
- PR Newswire
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces key sepsis-related events, sponsorships and studies in conjunction with World Sepsis Day today and Sepsis Awareness Month (September).
- PR Newswire
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, "Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D)," in the United States to support FDA marketing approval. This is being performe
